Evidence map›Paper›PMID 33492646›Full record

GuidelineAnnals of nuclear medicine2021

Clinical practice guidelines for high-resolution breast PET, 2019 edition.

Yoko Satoh, Masami Kawamoto, Kazunori Kubota, Koji Murakami, Makoto Hosono, Michio Senda, Masayuki Sasaki, Toshimitsu Momose, Kengo Ito, Terue Okamura and 18 more

Open access · hybridAbstract readPractice Guideline
In one paragraph

Guideline in Annals of nuclear medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. IsFrontiers in oncology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 2 institutions in 1 country.

Yoko SatohPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan. ysatoh@ypic.jp.ORCID http://orcid.org/0000-0002-0188-0906
Masami KawamotoPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Kazunori KubotaJapanese Society of Nuclear Medicine, Tokyo, Japan.
Koji MurakamiPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Makoto HosonoPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Michio SendaPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Masayuki SasakiPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Toshimitsu MomosePET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Kengo ItoPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Terue OkamuraPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Keiichi OdaPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Yuji KugePET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Minoru SakuraiPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Ukihide TateishiPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Yasuhisa FujibayashiPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Yasuhiro MagataPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Takeshi YoshidaPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Atsuo WakiPET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Katsuhiko KatoHealth Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Teisuke HashimotoHealth Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Mayuki UchiyamaHealth Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Seigo KinuyaHealth Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Tatsuya HigashiHealth Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Yasuhiro MagataHealth Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Akihiro MachitoriHealth Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Hirotaka MarunoHealth Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Ryogo MinamimotoHealth Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Keiichiro YoshinagaHealth Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan.
Japanese Society of Medical Oncology · JPThe Japanese Society of Gastroenterological Surgery · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast positron emission tomography (PET) has had insurance coverage when performed with conventional whole-body PET in Japan since 2013. Together with whole-body PET, accurate examination of breast cancer and diagnosis of metastatic disease are possible, and are expected to contribute significantly to its treatment planning. To facilitate a safer, smoother, and more appropriate examination, the Japanese Society of Nuclear Medicine published the first edition of practice guidelines for high-resolution breast PET in 2013. Subsequently, new types of breast PET have been developed and their clinical usefulness clarified. Therefore, the guidelines for breast PET were revised in 2019. This article updates readers as to what is new in the second edition. This edition supports two different types of breast PET depending on the placement of the detector: the opposite-type (positron emission mammography; PEM) and the ring-shaped type (dedicated breast PET; dbPET), providing an overview of these scanners and appropriate imaging methods, their clinical applications, and future prospects. The name "dedicated breast PET" from the first edition is widely used to refer to ring-shaped type breast PET. In this edition, "breast PET" has been defined as a term that refers to both opposite- and ring-shaped devices. Up-to-date breast PET practice guidelines would help provide useful information for evidence-based breast imaging.

Indexed as

BreastBreast NeoplasmsPositron-Emission TomographyFemaleHumansBreast PETFDGGuidelinesJapanese society of nuclear medicineRevised edition

Identifiers

PMID33492646
PMCPMC7902575
OpenAlexW3125596912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.